Ross Jensen
Optometrist · Appleton, WINPI 1568758183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,070, 2.3 times the $466 reported in 2019. Among optometrist clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$630
- AbbVie$611
- Bausch & Lomb Americas Inc.$593
- Novartis$415
- Amgen$398
- Alcon$306
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$4,69497%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 57 | $630 |
| AbbVie(2 entities) | 38 | $611 |
| Bausch & Lomb Americas Inc. | 32 | $593 |
| Novartis | 26 | $415 |
| Amgen(2 entities) | 12 | $398 |
| Alcon | 13 | $306 |
| Dompe US, Inc. | 11 | $262 |
| Astellas Pharma US Inc | 6 | $245 |
| Mallinckrodt Hospital Products Inc. | 7 | $228 |
| Oyster Point Pharma, Inc. | 13 | $215 |
| Sun Pharmaceutical Industries Inc. | 5 | $177 |
| Kala Pharmaceuticals, Inc. | 9 | $165 |
| Rxsight Inc | 5 | $158 |
| Coopervision Inc. | 9 | $146 |
| Tarsus Pharmaceuticals, Inc. | 5 | $92 |
| Shire North American Group Inc | 4 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Glaukos Corporation | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,820 in reported general payments places this provider in the 95th percentile of 867 optometrist providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 18 | $19,977 |
| RestasisCyclosporine | 14 | $14,833 |
| Loteprednol Etabonate | 38 | $9,019 |
| Prednisolone Acetate | 171 | $6,462 |
| Cyclosporine | 12 | $6,326 |
| Latanoprost | 214 | $2,868 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,631 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,373 |
| ValacyclovirValacyclovir Hcl | 20 | $1,764 |
| Timolol Maleate | 63 | $1,037 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $843 |
| Brimonidine Tartrate | 26 | $487 |
| Ketorolac Tromethamine | 28 | $451 |
| Dorzolamide Hcl | 14 | $425 |
| Ofloxacin | 29 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $593 | $19,97718 claims |
| AbbVieRestasis | $611 | $14,83314 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $630 | $9,01938 claims |
| AlconSimbrinza | $306 | $2,37312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 867 optometrist providers in Wisconsin.
Other optometrist in Appleton
- Mark WadeAppleton$8K
- Robert SchulzAppleton$6K
- Bradley JorgensenAppleton$5K
- Mindy HarringtonAppleton$5K
- Elizabeth MelchertAppleton$4K
- David NelsonMadison$256K
- Jennifer FrieheMukwonago$234K
- Tessa SokolMadison$105K
- Christopher LopezClintonville$48K
- Jeff BanasMount Pleasant$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.